These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 8136746)
1. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Locatelli F; Uderzo C; Dini G; Zecca M; Arcese W; Messina C; Andolina M; Miniero R; Porta F; Rovelli A Bone Marrow Transplant; 1993 Dec; 12(6):627-33. PubMed ID: 8136746 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
3. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972 [TBL] [Abstract][Full Text] [Related]
5. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Ochs LA; Miller WJ; Filipovich AH; Haake RJ; McGlave PB; Blazar BR; Ramsay NK; Kersey JH; Weisdorf DJ Bone Marrow Transplant; 1994 Apr; 13(4):455-60. PubMed ID: 8019471 [TBL] [Abstract][Full Text] [Related]
6. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
7. Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO). Dini G; Cancedda R; Giorgiani G; Porta F; Messina C; Uderzo C; Pession A; Fagioli F; La Nasa G; Arcese W; Pollichieni S; Zecca M; Lanino E; Mazzolari E; Cesaro S; Balduzzi A; Rondelli R; Vassallo E; Cappelli B; Locatelli F; Haematologica; 2002 Aug; 87(8 Suppl):51-7. PubMed ID: 12412391 [TBL] [Abstract][Full Text] [Related]
8. [Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings]. Morimoto T; Hattori K; Yabe H; Yabe M; Hinohara T; Shimizu T; Matsumoto M; Hagihara M; Tsuji K; Kato S Rinsho Ketsueki; 1998 Sep; 39(9):631-9. PubMed ID: 9796395 [TBL] [Abstract][Full Text] [Related]
9. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946 [TBL] [Abstract][Full Text] [Related]
10. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
11. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048 [TBL] [Abstract][Full Text] [Related]
12. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings. Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376 [TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G Bone Marrow Transplant; 2003 Nov; 32(9):881-7. PubMed ID: 14561988 [TBL] [Abstract][Full Text] [Related]
14. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T; Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936 [TBL] [Abstract][Full Text] [Related]
15. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. Koga Y; Nagatoshi Y; Kawano Y; Okamura J Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323 [TBL] [Abstract][Full Text] [Related]
17. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714 [TBL] [Abstract][Full Text] [Related]
18. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Eisner MD; August CS Bone Marrow Transplant; 1995 May; 15(5):663-8. PubMed ID: 7670393 [TBL] [Abstract][Full Text] [Related]
19. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Aschan J; Ringdén O; Sundberg B; Gahrton G; Ljungman P; Winiarski J Bone Marrow Transplant; 1991 Feb; 7(2):113-9. PubMed ID: 2049554 [TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]